Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial – Authors' reply

Masatoshi Kudo; Zhenggang Ren; Richard S. Finn; Josep M. Llovet

doi:10.1016/s0140-6736(25)01441-2

Related publications

Article2022

LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)

Anthony B. El-Khoueiry, Josep M. Llovet, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zhenggang Ren, Kalgi Mody, Jerry J Li, Abby B. Siegel, Leonid Dubrovsky, Masatoshi Kudo

Journal of Clinical Oncology

Article2001

Ethical Issues in the Reporting of Clinical Trials—Reply

Kenneth F. Schulz, David Moher, Douglas G. Altman

Article2020

Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial.

Ho Yeong Lim, Philippe Merle, Richard S. Finn, Catherine Frenette, Gianluca Masi, Masafumi Ikeda, Hong Zebger‐Gong, Sabine Fiala-Buskies, Kirhan Özgürdal, Masatoshi Kudo, Shukui Qin

Article2025

Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

Richard S. Finn, Masashi Kudo, P. Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruliang Xu, Julien Edeline, B-Y Ryoo, Zhenggang Ren, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, H. Kumada, S. Kamble, Josephine M. Norquist, Kabir Mody, Andrew Z. Wang, Leonid Dubrovsky, Josep M. Llovet

Article2023

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Richard S. Finn, Shukui Qin, Masatoshi Kudo, Tim Meyer, Frédéric Boisserie, Songzi Li, Yaxi Chen, Gisoo Barnes, Ramil Abdrashitov, Andrew X. Zhu, Arndt Vogel